| Bid | 6.99 |
| Market Cap | 564.18M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.35 |
| PE Ratio (ttm) | -3.09 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 8 |
| Volume | 757,714 |
| Avg. Volume (20D) | 1,751,478 |
| Open | 7.30 |
| Previous Close | 7.24 |
| Day's Range | 7.05 - 7.32 |
| 52-Week Range | 6.98 - 24.17 |
| Beta | undefined |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, includi...
Analyst Forecast
According to 11 analyst ratings, the average rating for KURA stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 341.08% from the latest price.
3 weeks ago · seekingalpha.com
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)Kura Oncology, Inc.'s collaboration with Kyowa Kirin brings $330M upfront and a potential $1.2B in milestone payments, enhancing long-term shareholder value despite initial market disappointment. Zift...
